NASDAQ:BCYC Bicycle Therapeutics (BCYC) Stock Price, News & Analysis $9.30 +0.22 (+2.42%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$9.16 -0.14 (-1.45%) As of 05/2/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Bicycle Therapeutics Stock (NASDAQ:BCYC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bicycle Therapeutics alerts:Sign Up Key Stats Today's Range$9.13▼$9.5550-Day Range$6.38▼$11.3252-Week Range$6.10▼$28.67Volume192,612 shsAverage Volume396,144 shsMarket Capitalization$643.58 millionP/E RatioN/ADividend YieldN/APrice Target$26.00Consensus RatingModerate Buy Company OverviewBicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Read More… Bicycle Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreBCYC MarketRank™: Bicycle Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 686th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBicycle Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageBicycle Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bicycle Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($3.06) to ($3.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicycle Therapeutics is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicycle Therapeutics is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.95% of the float of Bicycle Therapeutics has been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Bicycle Therapeutics has recently decreased by 27.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.95% of the float of Bicycle Therapeutics has been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Bicycle Therapeutics has recently decreased by 27.21%, indicating that investor sentiment is improving significantly. News and Social Media1.7 / 5News Sentiment0.05 News SentimentBicycle Therapeutics has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Bicycle Therapeutics this week, compared to 5 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,710.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Bicycle Therapeutics is held by insiders.Percentage Held by Institutions86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bicycle Therapeutics' insider trading history. Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCYC Stock News HeadlinesBicycle Therapeutics plc (NASDAQ:BCYC) CEO Sells $17,940.74 in StockApril 5, 2025 | insidertrades.comBarclays Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)May 3 at 4:09 AM | theglobeandmail.comElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.May 3, 2025 | Brownstone Research (Ad)Bicycle Therapeutics price target lowered to $15 from $40 at BarclaysMay 2 at 6:07 PM | finance.yahoo.comBicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025May 1 at 11:16 PM | seekingalpha.comBicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial ResultsMay 1 at 11:16 PM | finance.yahoo.comBicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This DiscountedApril 22, 2025 | seekingalpha.com1BCYC : Analyst Expectations For Bicycle Therapeutics's FutureApril 9, 2025 | benzinga.comSee More Headlines BCYC Stock Analysis - Frequently Asked Questions How have BCYC shares performed this year? Bicycle Therapeutics' stock was trading at $14.00 at the beginning of 2025. Since then, BCYC stock has decreased by 33.6% and is now trading at $9.30. View the best growth stocks for 2025 here. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics plc (NASDAQ:BCYC) issued its earnings results on Thursday, May, 1st. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by $0.02. The business had revenue of $9.98 million for the quarter, compared to analyst estimates of $8.67 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative trailing twelve-month return on equity of 27.35%. When did Bicycle Therapeutics IPO? Bicycle Therapeutics (BCYC) raised $64 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Bicycle Therapeutics' major shareholders? Bicycle Therapeutics' top institutional shareholders include Principal Financial Group Inc. (0.91%), Harbor Capital Advisors Inc. (0.21%), Cerity Partners LLC (0.02%) and Exchange Traded Concepts LLC (0.02%). Insiders that own company stock include Bros Advisors Lp Baker, Kevin Lee, Michael Skynner, Alistair Milnes, Santiago Arroyo, Nicholas Keen, Michael Charles Ferguso Hannay, Nigel Crockett, Alethia Young, Travis Alvin Thompson and Lee Kalowski. View institutional ownership trends. How do I buy shares of Bicycle Therapeutics? Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Vale (VALE), uniQure (QURE), Clean Energy Fuels (CLNE), Paycom Software (PAYC), Grayscale Ethereum Trust (ETH) (ETHE), Curaleaf (CURLF) and Marathon Oil (MRO). Company Calendar Last Earnings5/01/2025Today5/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCYC CIK1761612 Webwww.bicycletherapeutics.com Phone441223261503FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Stock Price Target$26.00 High Stock Price Target$48.00 Low Stock Price Target$14.00 Potential Upside/Downside+179.6%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-180,660,000.00 Net Margins-450.64% Pretax Margin-459.75% Return on Equity-27.35% Return on Assets-20.81% Debt Debt-to-Equity RatioN/A Current Ratio17.13 Quick Ratio17.13 Sales & Book Value Annual Sales$35.28 million Price / Sales18.24 Cash FlowN/A Price / Cash FlowN/A Book Value$12.35 per share Price / Book0.75Miscellaneous Outstanding Shares69,202,000Free Float63,177,000Market Cap$643.58 million OptionableOptionable Beta1.40 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:BCYC) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.